Program
bexicaserin
Also written as “LP352” and “LP352, bexicaserin”.
Its studies are mostly in Epilepsies, Myoclonic · Seizures, led by H. Lundbeck.
Furthest: phase 3, since Oct 24, 20245 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| H. Lundbeck | 53 open or running | phase 3since Oct 24, 2024 | Mar 22, 2022 | Dec 31, 2026phase 3 · NCT06660394 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 22, 2022First study: phase 2 study in Epilepsies, MyoclonicFirst studyNCT05364021 · 52 enrolled · United States, Australia
- Nov 15, 2022Phase 2 study in Epilepsies, MyoclonicNCT05626634 · 41 enrolled · United States, Australia
- Oct 24, 2024Phase 3 study in Epilepsies, MyoclonicNCT06660394 · 108 enrolled · United States, Australia, Belgium and more
- Dec 2, 2024Phase 3 study in SeizuresNCT06719141 · 367 enrolled · United States, Australia, Belgium and more
- Mar 6, 2025Phase 3 study in SeizuresNCT06908226 · 324 planned · United States, Australia, Belgium and more
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Epilepsies, MyoclonicNCT06660394
- Nov 11, 2027Primary completion: phase 3 study in SeizuresNCT06908226
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06908226Seizures · United States, Australia, Belgium and more | 3 | By invitation | Nov 11, 2027 | 324 |
| NCT06719141Seizures · United States, Australia, Belgium and more | 3 | Active, not recruiting | Oct 31, 2026 | 367 |
| NCT06660394Epilepsies, Myoclonic · United States, Australia, Belgium and more | 3 | Active, not recruiting | Dec 31, 2026 | 108 |
| NCT05626634Epilepsies, Myoclonic · United States, Australia | 2 | Completed | Dec 20, 2024 | 41 |
| NCT05364021Epilepsies, Myoclonic · United States, Australia | 2 | Completed | Nov 16, 2023 | 52 |
How it is read
Names in the registry
- “LP352”, 4 entries
- “LP352, bexicaserin”, 1 entry
Conditions, from the studies’ own filings
- Epilepsies, Myoclonic, 3 studies
- Seizures, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.